ReGelTec Announces First Patient Treated in U.S. IDE Clinical Trial for HYDRAFIL System to Treat Chronic Low Back Pain
BALTIMORE--(BUSINESS WIRE)--Jun 18, 2025--
ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has treated the first patient in its HYDRAFIL-D FDA investigational device exemption (IDE) clinical trial for its HYDRAFIL ® System for disc augmentation. The patient was enrolled by Kas Amirdelfan, M.D., an interventional pain physician and founding member of Boomerang Healthcare, Inc. in Walnut Creek, Calif. The HYDRAFIL System is an outpatient procedure offering interventional pain physicians and patients a new treatment designed to reduce pain and improve daily function without the need for an invasive surgery.
The launch of the HYDRAFIL-D U.S. study follows the company's receipt of CE Mark for the HYDRAFIL System based on promising results of clinical studies performed outside the United States on 75 patients. The studies showed that patients treated with HYDRAFIL experienced clinically and statistically significant improvements in pain and disability, with more than 80% improvement in Oswestry Disability Index (ODI) scores and greater than 70% reduction in Numeric Pain Rating Scale scores, with reductions sustained for two years in the 63 patients that have completed their two-year follow-up visit.
'An overwhelming majority of my chronic low back pain patients either do not want or are not good candidates for invasive spine surgeries, yet they continue to feel debilitated, without many treatment options,' said Dr. Amirdelfan. 'The early data on HYDRAFIL is compelling and promising for our subjects. I am excited to be working with ReGelTec and the other principal investigators to enroll the HYDRAFIL-D Study and evaluate the impact of HYDRAFIL on patients with degenerative disc disease.'
The HYDRAFIL-D study is a 225-patient, multicenter, single-blinded, randomized, controlled trial evaluating the safety and effectiveness of the HYDRAFIL System to support FDA approval. The study will measure improvements in pain and disability, reliance on opioid medications, and the need for invasive medical procedures in patients with chronic low back pain due to degenerative disc disease. The protocol includes an interim safety analysis when the first sixty patients complete their six-month follow-up visit. There are nine study sites currently enrolling patients in Birmingham, Ala.; Walnut Creek, Calif.; Greenwood Village, Colo.; Jasper, Ga.; Shreveport, La.; Edmond, Okla.; Tyler, Texas; Richmond, Virginia; and Calgary, Canada, with additional sites being added.
More than one in 10 U.S. adults suffer from chronic low back pain. 1 About 42% of this population, or more than 10 million Americans, has degenerative disc disease 2, a condition that is the largest contributor to chronic low back pain where intervertebral discs in the spine deteriorate and lose their height and volume. Degenerating discs cause vertebrae to move abnormally and inflame surrounding spinal structures, muscles, joints and nerves, resulting in pain in the back and sometimes the leg.
Performed in an outpatient procedure under local anesthesia, ReGelTec's HYDRAFIL System delivers a permanent hydrogel into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. When the hydrogel implant solidifies in the disc, it distributes the load and strain felt in that intervertebral segment to improve function and reduce the pain signaling to the brain.
'I have been working with doctors and scientists for more than twenty years to develop a treatment for chronic low back pain, and in HYDRAFIL, we believe we've built a low-risk, effective option to fill a major market need,' said Tony Lowman, the inventor of HYDRAFIL and founder of ReGelTec. 'We look forward to fully enrolling the trial and securing FDA approval for the HYDRAFIL System so that patients in the United States with degenerative disc disease can benefit from this innovative, minimally invasive treatment option.'
Patients interested in learning more about the HYDRAFIL-D Study can visit www.hydrafilstudy.com.
ABOUT REGELTEC, INC.
ReGelTec is a clinical-stage privately held biomedical company dedicated to developing and commercializing a percutaneous hydrogel implant for the treatment of chronic low back pain due to degenerative disc disease. ReGelTec's HYDRAFIL System is an outpatient disc augmentation procedure where a permanent hydrogel is delivered into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. For more information, please visit https://regeltec.com/.
1 Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-1694. doi: 10.1002/acr.22890. PMID: 26991822; PMCID: PMC5027174.
2 Michael J. DePalma, Jessica M. Ketchum, Thomas Saullo, What Is the Source of Chronic Low Back Pain and Does Age Play a Role?, Pain Medicine, Volume 12, Issue 2, February 2011, Pages 224–233, https://doi.org/10.1111/j.1526-4637.2010.01045.x
View source version on businesswire.com:https://www.businesswire.com/news/home/20250618986847/en/
CONTACT: MEDIA CONTACT:
Sam Choinski
Pazanga Health Communications
(860) 301-5058
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA MARYLAND
INDUSTRY KEYWORD: RESEARCH SURGERY MEDICAL DEVICES FDA HOSPITALS CLINICAL TRIALS HEALTH TECHNOLOGY HEALTH SCIENCE
SOURCE: ReGelTec Inc.
Copyright Business Wire 2025.
PUB: 06/18/2025 07:05 AM/DISC: 06/18/2025 07:04 AM
http://www.businesswire.com/news/home/20250618986847/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
34 minutes ago
- News24
Elon Musk's X Corp sues to block New York social media transparency law
• Elon Musk's X Corp has filed a federal lawsuit against a New York state law 'Stop Hiding Hate Act' that requires social media companies to submit semi-annual reports on how they moderate hate speech and disinformation. • X argues the law violates the First Amendment by forcing platforms to disclose sensitive moderation practices. • The law targets companies with over $100 million in annual revenue, imposes $15 000 daily fines for violations. Elon Musk's X Corp has filed a lawsuit challenging a New York state law that requires social media companies to report how they moderate hate speech and disinformation. The complaint, filed in a federal court in Manhattan, seeks to halt the law, which X argues violates the First Amendment by forcing platforms to disclose sensitive information about their content moderation practices. "Today, @X filed a First Amendment lawsuit against a New York law, NY S895B," X's Global Government Affairs team posted Tuesday, adding that it had successfully challenged a similar law in California. "X is the only platform fighting for its users by challenging the law, and we are confident we will prevail in this case as well," the company said. The New York law requires social media companies with more than $100 million in annual revenue to submit semi-annual reports detailing how they define and moderate hate speech, racism, extremism, disinformation and harassment. Companies face fines of $15 000 per day for violations, which can be sought by the attorney general's office. X says the law is "an impermissible attempt by the State to inject itself into the content-moderation editorial process" and seeks to pressure platforms into restricting constitutionally protected speech. The lawsuit comes after X successfully challenged a nearly identical California law last year, according to the filing. New York's law is "a carbon copy" of the California provisions that were struck down, the filing adds. X claims New York lawmakers refused to discuss changes to the bill after the California ruling, with sponsors saying they declined to meet because of content on X promoted by owner Musk that "threatens the foundations of our democracy." READ | Musk's X sues to block California anti-hate speech law The company argues this indicated "viewpoint discriminatory motives" behind the law's passage. Senator Brad Hoylman-Sigal and Assembly member Grace Lee - who introduced the law - said in a statement that their act "does not infringe upon the First Amendment rights of social media companies, nor does it conflict with federal law". "Instead, the Stop Hiding Hate Act requires narrowly tailored disclosures by social media companies to allow consumers to better decide which social media platforms they utilise," they added. "The fact that Elon Musk would go to these lengths to avoid disclosing straightforward information to New Yorkers as required by our statute illustrates exactly why we need the Stop Hiding Hate Act."
Bloomberg
43 minutes ago
- Bloomberg
Road to a $3.7 Trillion Stablecoin Market Is Full of Obstacles
The passage of stablecoin legislation in the US Senate marks a huge leap forward for the potential mainstreaming of cryptocurrencies that track the US dollar one-to-one. Yet there are still big problems to solve before many businesses can capitalize on the opportunities that are arising. Now, stablecoins are taking the leap from their original use as crypto-market poker chips to common mediums of exchange, offering merchants and consumers cheaper and more efficient payments systems.
Forbes
an hour ago
- Forbes
Supreme Court Upholds Ban On Gender-Affirming Care For Minors
The Supreme Court upheld Tennessee's law restricting gender-affirming medical treatments for minors, dealing a blow Wednesday to transgender rights that could have consequences nationwide, as more than two dozen states have imposed similar laws. This story is breaking and will be updated.
